TCRT ALAUNOS THERAPEUTICS INC Disposals and divestitures 8-K Filing 2024 - License Termination Alaunos Therapeutics terminated its license agreement with Precigen to develop T-cell receptors for cancer treatment, citing strategic priorities and the upcoming expiration of a patent in 2026, while also exploring various strategic alternatives and progressing its obesity drug program with plans for testing in 2024 and 2025.Get access to all SEC 8-K filings of the ALAUNOS THERAPEUTICS INC